UH Tech Bridge member Indapta Therapeutics has secured $22.5 million to advance clinical trials of its lead g-NK cell therapy, IDP-023, for cancer and autoimmune diseases. Backed by major investors and a $4.5 million CPRIT grant, Indapta鈥檚 progress reflects the strength of UH鈥檚 innovation ecosystem in driving biotech breakthroughs.